These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21398049)

  • 21. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Hodgkin's lymphoma of Waldeyer's ring in children: outcome using chemotherapy and involved field radiotherapy.
    Laskar S; Bahl G; Muckaden MA; Pai S; Nair R; Gupta S; Shet T; Gujral S; Arora B; Sengar M; Shrivastava SK; Dinshaw KA
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):613-8. PubMed ID: 18585015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of radiotherapy and combined modality treatment in early stage high grade non-Hodgkin's lymphoma.
    Frank C; Flentje M; Goldschmidt H; Hunstein W; Wannenmacher M
    Strahlenther Onkol; 1994 Jul; 170(7):383-90. PubMed ID: 8052937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indolent stage IE non-Hodgkin's lymphoma of the orbit: results after primary radiotherapy.
    Bischof M; Zierhut D; Neuhof D; Karagiozidis M; Treiber M; Roeder F; Debus J; Krempien R
    Ophthalmologica; 2007; 221(5):348-52. PubMed ID: 17728558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
    Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
    Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.
    Aref A; Narayan S; Tekyi-Mensah S; Varterasian M; Dan M; Eilender D; Karanes C; al-Katib A
    Radiat Oncol Investig; 1999; 7(3):186-91. PubMed ID: 10406061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.
    Girinsky T; Lapusan S; Ribrag V; Koscielny S; Ferme C; Carde P
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):476-9. PubMed ID: 15667970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).
    Rosenbluth BD; Yahalom J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1185-91. PubMed ID: 16682133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II.
    Barbieri E; Cammelli S; Mauro F; Perini F; Cazzola A; Neri S; Bunkheila F; Ferrari S; Brandoli V; Zinzani P; Mercuri M; Bacci G
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):760-4. PubMed ID: 15183479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
    Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Jóhannsson J; Specht L; Mejer J; Jensen BA
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1466-70. PubMed ID: 12459371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.
    Lowry L; Smith P; Qian W; Falk S; Benstead K; Illidge T; Linch D; Robinson M; Jack A; Hoskin P
    Radiother Oncol; 2011 Jul; 100(1):86-92. PubMed ID: 21664710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.